AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Truqap (capivasertib) — US product sales by Quarter
Truqap (capivasertib) — US product sales ($M) ($M)
AstraZeneca Truqap (capivasertib) — US product sales: $168M in Q2 2026, up 18.3% from a year earlier.
Where the Q2 2026 figure comes from
“|| Truqap | 233 | | 37 | | 37 | | 168 | | 18 | | 17 | | n/m | | n/m | | 34 | | n/m | | n/m | | 14 | | 77 | | 85”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Truqap (capivasertib) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 168 | +18.3% | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 138 | +24.3% | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 174 | +17.6% | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 159 | +33.6% | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 142 | +56.0% | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 111 | +122.0% | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 148 | +2,366.7% | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 119 | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 91 | – | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 50 | – | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 6 | – | Form 6-K FY2023Q4 Earnings Release ↗ |
Breakdown
What makes up truqap (capivasertib) — US product sales
Cite this data
StockData. (2026). AstraZeneca Truqap (capivasertib) — US product sales ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-truqap-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.